Sandoz reports strong 2024 results

5 March 2025

Swiss generics and biosimilars giant Sandoz (SIX: SDZ) today announced financial results for the full year 2024, showing that sales were$10.4 billion, up by 9% in constant currencies (+7% in $). Fourth-quarter net sales of $2.7 billion, up by 9% in constant currencies (+7% in $).

The majority of revenues came for generics, which came in at $7,504 million (+1% YoY, +2% CER), with biosimilars sales of $2,853(+29% YoY, +30% CER). Strong sales performances in all three regions, was driven by double-digit growth in biosimilars, both in the fourth quarter and full year, benefitting from recent launches and base-business momentum

Operating income of $307 million, was up by 5% in constant currencies (-18% in $). Core earnings before interest, tax, depreciation and amortization (EBITDA) were $2.08 billion, up 24% (+19 in $).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars